This Article Full Text Full Text (PDF) Correction (v69,p4092) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodriguez-Gonzalez, A. Articles by Sakamoto, K. M. Search for Related Content PubMed PubMed Citation Articles by Rodriguez-Gonzalez, A. Articles by Sakamoto, K. M. Related Collections Cellular Pathobiology: Metabolism and Physiology Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Role of the Aggresome Pathway in Cancer: Targeting Histone Deacetylase 6–Dependent Protein Degradation

¹ Division of Hematology-Oncology, Mattel Children's Hospital and ² Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California; and ³ Division of Biology, California Institute of Technology, Pasadena, California

Requests for reprints: Kathleen M. Sakamoto, Division of Hematology-Oncology, Mattel Children's Hospital University of California at Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90095-1752. Phone: 310-794-7007; Fax: 310-206-8089; E-mail: kms{at}ucla.edu.

Key Words: aggresomes • protein degradation • cancer • HDAC6 • ubiquitination • apoptosis

Misfolded or aggregated proteins have two fates: they are either refolded with the help of chaperones or degraded by the proteasome. Cells also have an alternative pathway that involves intracellular "storage bins" for misfolded intracellular proteins known as aggresomes. Aggresomes recruit motor proteins that transport misfolded or aggregated proteins to chaperones and proteasomes for subsequent destruction. There is emerging evidence that inhibiting the aggresome pathway leads to accumulation of misfolded proteins and apoptosis in tumor cells through autophagy. We discuss the role of aggresomes in cancer and the potential to target this pathway for therapy. [Cancer Res 2008;68(8):2557–60]

This article has been cited by other articles:

				A. A. Lane and B. A. Chabner Histone Deacetylase Inhibitors in Cancer Therapy J. Clin. Oncol., November 10, 2009; 27(32): 5459 - 5468. [Abstract] [Full Text] [PDF]

				A. Palijan, I. Fernandes, Y. Bastien, L. Tang, M. Verway, M. Kourelis, L. E. Tavera-Mendoza, Z. Li, V. Bourdeau, S. Mader, et al. Function of Histone Deacetylase 6 as a Cofactor of Nuclear Receptor Coregulator LCoR J. Biol. Chem., October 30, 2009; 284(44): 30264 - 30274. [Abstract] [Full Text] [PDF]

				M. Bots and R. W. Johnstone Rational Combinations Using HDAC Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3970 - 3977. [Abstract] [Full Text] [PDF]

				D. S. Schrump Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications Clin. Cancer Res., June 15, 2009; 15(12): 3947 - 3957. [Abstract] [Full Text] [PDF]

				L. Ellis, P. W. Atadja, and R. W. Johnstone Epigenetics in cancer: Targeting chromatin modifications Mol. Cancer Ther., June 1, 2009; 8(6): 1409 - 1420. [Abstract] [Full Text] [PDF]

				M. Milani, T. Rzymski, H. R. Mellor, L. Pike, A. Bottini, D. Generali, and A. L. Harris The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib Cancer Res., May 15, 2009; 69(10): 4415 - 4423. [Abstract] [Full Text] [PDF]

				Correction: Review Article on Aggresomes in Cancer Cancer Res., May 1, 2009; 69(9): 4092 - 4092. [Full Text] [PDF]

				M. Bazzaro, Z. Lin, A. Santillan, M. K. Lee, M.-C. Wang, K. C. Chan, R. E. Bristow, R. Mazitschek, J. Bradner, and R. B.S. Roden Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor Clin. Cancer Res., November 15, 2008; 14(22): 7340 - 7347. [Abstract] [Full Text] [PDF]